Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Vion (formerly Oncorx) interesting play on Gene Therapy -- Ignore unavailable to you. Want to Upgrade?

To: Jim Oravetz who wrote (333)	8/10/2006 1:05:23 PM
From: Jim Oravetz	Read Replies (1) \| Respond to of 370

Vion Pharmaceuticals 2Q Losses 10c/Shr Vs 8c/Shr >VION August 8, 2006 6:12 p.m. WASHINGTON (Dow Jones)--Vion Pharmaceuticals Inc. (VION) reported Tuesday that its second-quarter net loss widened to $6.9 million, or 10 cents a share, from a net loss of $5.1 million, or 8 cents a share, for the same period a year ago. The New Haven, Conn., development-stage biopharmaceutical company had $1,000 in revenue from technology license fees during the three months ended June 30, compared with $7,000 in revenue in the second quarter of 2005, according to the company's quarterly report filed Tuesday with the Securities and Exchange Commission. The company said its operating expenses increased by 34% to $7.4 million, from $5.6 million a year ago.